Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval
Yusimry Biosimilar To Humira Set For 1 July 2023 Launch, After Multiple Rivals
• By David Wallace
Coherus must wait until mid-2023 to make its “compelling value proposition” • Source: Alamy 
